跳轉至內容
Merck
全部照片(1)

重要文件

C2100000

胆钙化醇

European Pharmacopoeia (EP) Reference Standard

同義詞:

(+)-维生素 D3, 活化7-脱氢胆固醇, 活化7-脱氢胆甾醇, 胆骨化醇

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C27H44O
CAS號碼:
分子量::
384.64
Beilstein:
2339331
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

生物源

synthetic

等級

pharmaceutical primary standard

agency

EP

API 家族

cholecalciferol

形狀

solid

製造商/商標名

EDQM

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

mp

83-86 °C (lit.)

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

−20°C

SMILES 字串

CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C

InChI

1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1

InChI 密鑰

QYSXJUFSXHHAJI-YRZJJWOYSA-N

基因資訊

human ... VDR(7421)

尋找類似的產品? 前往 產品比較指南

一般說明

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。

胆钙化醇是一种脂溶性维生素,商业上用于维生素补充剂和杀鼠剂。它可通过暴露于阳光直接合成或通过正常的膳食摄取。

應用

本欧洲药典参考标准仅用于欧洲药典中明确规定的用途。

生化/生理作用

维生素 D 借以发挥作用的受体是配体依赖性转录因子超家族的成员。调控正常细胞和癌细胞的增殖和分化。对乳腺癌、结肠癌和前列腺癌细胞具有抗增殖和抗转移作用。肠和骨骼中的活化维生素 D 受体维持着钙的吸收和平衡。

包裝

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他說明

可能适用相应的销售限制。

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Clinical Veterinary Toxicology (2003)
Simultaneous determination of retinol acetate, retinol palmitate, cholecalciferol, α-tocopherol acetate and alphacalcidol in capsules by non-aqueous reversed-phase HPLC and column backflushing
Wielinski S and Olszanowski A
Chromatographia, 50(1-2), 109-112 (1999)
Sina Gallo et al.
JAMA, 309(17), 1785-1792 (2013-05-02)
Vitamin D supplementation in infancy is required to support healthy bone mineral accretion. A supplement of 400 IU of vitamin D per day is thought to support plasma 25-hydroxyvitamin D (25[OH]D) concentrations between 40 and 50 nmol/L; some advocate 75
Sara S Oberhelman et al.
Mayo Clinic proceedings, 88(12), 1378-1387 (2013-12-03)
To determine whether a single monthly supplement is as effective as a daily maternal supplement in increasing breast milk vitamin D to achieve vitamin D sufficiency in their infants. Forty mothers with exclusively breast-fed infants were randomized to receive oral
Cameron C Grant et al.
Pediatrics, 133(1), e143-e153 (2013-12-18)
To determine the vitamin D dose necessary to achieve serum 25-hydroxyvitamin D (25(OH)D) concentration ≥ 20 ng/mL during infancy. A randomized, double-blind, placebo-controlled trial in New Zealand. Pregnant mothers, from 27 weeks' gestation to birth, and then their infants, from

條款

This application demonstrates the suitability of the Ascentis Express C18, 5 μm, for the routine analysis of the fat-soluble vitamins D2 and D3 . Structures along with the optimized chromatogram obtained on the Ascentis Express C18, 5 μm are presented.

Separation of Ergocalciferol (D2), analytical standard; Cholecalciferol (D3), analytical standard

Separation of Ergocalciferol (D2), analytical standard; Cholecalciferol (D3), analytical standard

查看全部

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務